van der Straten L, Stege CAM, Kersting S, Nasserinejad K, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood 2023;142:1131-1142.
PMID: 37363833